Search Result

Results for "

butyrylcholinesterase inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Aldehyde Dehydrogenase (ALDH) (1) Amyloid-β (14) Apoptosis (4) Beta-secretase (3) Cannabinoid Receptor (2) Carbonic Anhydrase (1) Caspase (1) CCR (1) Cholinesterase (ChE) (81) Complement System (1) Cytochrome P450 (1) Drug Intermediate (1) Endogenous Metabolite (2) Epoxide Hydrolase (2) FAAH (1) GSK-3 (1) Histamine Receptor (1) Histone Acetyltransferase (2) IKK (2) Insecticide (1) Interleukin Related (4) Isotope-Labeled Compounds (4) JNK (3) Keap1-Nrf2 (1) mAChR (1) Monoamine Oxidase (4) NF-κB (4) NO Synthase (1) NOD-like Receptor (NLR) (4) p38 MAPK (1) Parasite (1) Potassium Channel (2) Reactive Oxygen Species (ROS) (3) Reference Standards (4) SOD (1) Tau Protein (4) TNF Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (2) γ-secretase (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (83)

By Targets:

5-HT Receptor (1)

Aldehyde Dehydrogenase (ALDH) (1)

Amyloid-β (14)

Apoptosis (4)

Beta-secretase (3)

Cannabinoid Receptor (2)

Carbonic Anhydrase (1)

Caspase (1)

CCR (1)

Cholinesterase (ChE) (81)

Complement System (1)

Cytochrome P450 (1)

Drug Intermediate (1)

Endogenous Metabolite (2)

Epoxide Hydrolase (2)

FAAH (1)

GSK-3 (1)

Histamine Receptor (1)

Histone Acetyltransferase (2)

IKK (2)

Insecticide (1)

Interleukin Related (4)

Isotope-Labeled Compounds (4)

JNK (3)

Keap1-Nrf2 (1)

mAChR (1)

Monoamine Oxidase (4)

NF-κB (4)

NO Synthase (1)

NOD-like Receptor (NLR) (4)

p38 MAPK (1)

Parasite (1)

Potassium Channel (2)

Reactive Oxygen Species (ROS) (3)

Reference Standards (4)

SOD (1)

Tau Protein (4)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

TRP Channel (2)

γ-secretase (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (9)

Metabolic Disease (2)

Neurological Disease (83)

Inhibitors & Agonists

Fluorescent Dyes

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107569

Garcinol 5 Publications Verification	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite	Inflammation/Immunology Cancer
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards *acetyl cholinesterase* (AChE)** and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 μM and 7.39 μM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-17368

Rivastigmine 1 Publications Verification ENA 713 free base; SDZ-ENA 713 free base	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-131922

Iso-OMPA Tetraisopropyl pyrophosphoramide	Cholinesterase (ChE)	Neurological Disease
Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of the irreversible butyrylcholinesterase (BuChE). Iso-OMPA enhances soman toxicity in rats associated with the inhibition of plasma carboxylesterase (CarbE) .

HY-11017

Rivastigmine tartrate 1 Publications Verification ENA 713; SDZ-ENA 713	Cholinesterase (ChE)	Neurological Disease
Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-112076

Atropine methyl bromide Methylatropine bromide	mAChR	Neurological Disease
Atropine methyl bromide (Methylatropine bromide), an antagonist of muscarinic acetylcholine receptors (mAChR), is a quaternary ammonium salt of atropine and an active molecule used for pupil dilation during ophthalmic examinations. Due to its high polarity, it is used to relieve pyloric spasm in infants. It is less likely than atropine to cross the central nervous system .

HY-B1239

Drofenine hydrochloride 1 Publications Verification Hexahydroadiphenine hydrochloride	Cholinesterase (ChE) Potassium Channel Amyloid-β TRP Channel Tau Protein NOD-like Receptor (NLR) JNK NF-κB IKK	Neurological Disease Metabolic Disease Inflammation/Immunology
Drofenine (Cycloadiphene; Hexahydroadiphenine) hydrochloride is an brain-penetrant antispasmodic agent. Drofenine hydrochloride is a Kv2.1 channel inhibitor with human IC₅₀ of 9.53 μM. Drofenine hydrochloride is a butyrylcholinesterase (BChE) inhibitor with K_i of 0.003 mM, and is a TRPV3 activator. Drofenine hydrochloride blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine hydrochloride induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine hydrochloride ameliorates diabetic peripheral neuropathy -like pathology. Drofenine hydrochloride can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm .

HY-N6009

8-Deoxygartanin	Parasite NF-κB	Infection
8-Deoxygartanin, a prenylated xanthones from G. mangostana, is a selective inhibitor of butyrylcholinesterase (BChE) . 8-Deoxygartanin exhibits antiplasmodial activity with an IC₅₀ of 11.8 μM for the W2 strain of Plasmodium falciparum . 8-Deoxygartanin inhibits NF-κB (p65) activation with an IC₅₀ of 11.3 μM .

HY-122140

ACG548B	Cholinesterase (ChE)	Neurological Disease
ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and BChE) with IC₅₀s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE affinity and selectivity over BChE and ChoK (choline kinase). ACG548B can be uesd for the study of myasthenia gravis and neuromuscular blockade .

HY-N10488

BChE-IN-11	Cholinesterase (ChE)	Neurological Disease
BChE-IN-11 (compound 10) is a potent, selective and non-competitive BChE (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

HY-131922R

Iso-OMPA (Standard) Tetraisopropyl pyrophosphoramide (Standard)	Cholinesterase (ChE) Reference Standards	Neurological Disease
Iso-OMPA (Standard) is the analytical standard of Iso-OMPA. This product is intended for research and analytical applications. Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of the irreversible butyrylcholinesterase (BuChE). Iso-OMPA enhances soman toxicity in rats associated with the inhibition of plasma carboxylesterase (CarbE) .

HY-150003

Aβ1–42 aggregation inhibitor 1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

HY-17368R

Rivastigmine (Standard) ENA 713 free base(Standard); SDZ-ENA 713 free base(Standard)	Reference Standards Cholinesterase (ChE)	Neurological Disease
Rivastigmine (Standard) is the analytical standard of Rivastigmine. This product is intended for research and analytical applications. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-N10781

Isograndifoliol	Cholinesterase (ChE)	Cardiovascular Disease Neurological Disease Cancer
Isograndifoliol is a selective inhibitor of *butyrylcholinesterase* (BChE) with an IC₅₀ value of 0.9 μM. And Isograndifoliol moderately inhibits acetylcholinesterase (AChE) with an IC₅₀ value of 342.9 μM. Isograndifoliol also has vasorelaxant effect and anti-tumor effect. Isograndifoliol can be used for research against dementia caused by neurodegenerative diseases .

HY-179496

ChE/GSK-3β-IN-1	GSK-3 Cholinesterase (ChE) Amyloid-β	Neurological Disease
ChE/GSK-3β-IN-1 (compound 18o) is a potent dual ChE/GSK-3β inhibitor. ChE/GSK-3β-IN-1 exhibits dual inhibition of AChE (IC₅₀ = 1.7 μM), butyrylcholinesterase (BChE) (IC₅₀ = 5.3 μM), and GSK-3β (IC₅₀ = 5.7 μM). ChE/GSK-3β-IN-1 inhibits Aβ1-42 self-aggregation. ChE/GSK-3β-IN-1 can be used for Alzheimer’s disease (AD) research .

HY-178943

Neuroprotective agent 15	Cholinesterase (ChE) Cannabinoid Receptor Aldehyde Dehydrogenase (ALDH) Caspase Apoptosis	Neurological Disease
Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC₅₀ values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, LDH release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .

HY-151562

AChE/BuChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC₅₀s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ₁ and σ₂ receptors with K_i values of 42.8 nM (human σ₁ receptor) and 191 nM (rat σ₂ receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .

HY-175816

5-HT6R/FAAH modulator 1	5-HT Receptor FAAH Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
5-HT6R/FAAH modulator 1 is a selective serotonin 5-HT6 receptor ligand and the fatty acid amide hydrolase (FAAH) enzyme inhibitor. 5-HT6R/FAAH modulator 1 shows a pK_i of 6.33 (5-HT6) and a pIC₅₀ valuesof 6.29 (FAAH). 5-HT6R/FAAH modulator 1 also slightly inhibits acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) enzymes (pIC₅₀ = 5.12). 5-HT6R/FAAH modulator 1 can inhibit apoptosis and reduce ROS levels. 5-HT6R/FAAH modulator 1 can be used for the research of neurological disease, such as Alzheimer’s disease (AD) .

HY-144446

BuChE-IN-1	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-1 (Compound 23) is a potent inhibitor of butyrylcholinesterase (BuChE). Butyrylcholinesterase (BuChE) is recently regarded as a biomarker in progressed Alzheimer’s disease (AD). BuChE-IN-1 shows low cytotoxicity and high blood brain barrier (BBB) permeability. BuChE-IN-1 is a promising BuChE inhibitor for the research of AD .

HY-16183

Echothiopate iodide Echothiophate iodide	Cholinesterase (ChE)	Neurological Disease
Echothiopate iodide is a potent hBChE (human butyrylcholinesterase) inhibitor. Echothiopate iodide is a long-acting anticholinesterase agent. Echothiopate iodide can be used for glaucoma research .

HY-157982

BChE-IN-28	Cholinesterase (ChE)	Neurological Disease
BChE-IN-28 (compound 6J) is a selective butyrylcholinesterase (BChE) inhibitor with an IC₅₀ of 8 nM and a K_i of 12.16 nM. BChE-IN-28 shows the lower inhibition against AChE, MAO-A and MAO-B .

HY-114320

BuChE-IN-TM-10 TM-10	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-TM-10 (TM-10) is a potent butyrylcholinesterase (BuChE) inhibitor, with an IC₅₀ of 8.9 nM. BuChE inhibitor 1 inhibits and disaggregates self-induced Aβ aggregation, exhibiting potent antioxidant activity and good blood-brain barrier (BBB) penetration. Has potential to treat Alzheimer’s disease .

HY-N12581

Kuwanon U	Cholinesterase (ChE)	Neurological Disease
Kuwanon U is a potent *cholinesterase* inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-119292

AP2238	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor with K_i values for human AChE (HuAChE) and butyrylcholinesterase (BuChE) of 21.7 and 48.9 μM respectively. AP2238 blocks the pro-fibrotic interaction between the peripheral site of AChE and Aβ, and can inhibit Aβ aggregation. AP2238 can be used for the research of Alzheimer's disease .

HY-149087

MR2938	Cholinesterase (ChE) NF-κB Interleukin Related TNF Receptor CCR NOD-like Receptor (NLR) JNK NO Synthase	Neurological Disease Inflammation/Immunology
MR2938 is a potent AChE inhibitor, with an IC₅₀ of 5.04 μM. MR2938 also suppresses NO production obviously (IC₅₀ = 3.29 μM). MR2938 suppresses the neuroinflammation through blocking MAPK/JNK and NF-κB signaling pathways. MR2938 can be used for Alzheimer’s disease (AD) research .

HY-178017

BChE/hCA II-IN-1	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease
BChE/hCA II-IN-1 (Compound 20) is a dual-functional inhibitor of Butyrylcholinesterase (BChE) and human carbonic anhydrase II (hCA II) with IC₅₀s of 76.50 and 10.69  μM for BChE and hCA II, respectively. BChE/hCA II-IN-1 can be used for neurodegenerative diseases like Alzheimer's and glaucoma research .

HY-107569R

Garcinol (Standard)	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite Reference Standards	Inflammation/Immunology Cancer
Garcinol (Standard) is the analytical standard of Garcinol. This product is intended for research and analytical applications. Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50s of 0.66 μM and 7.39 μM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC50= 7 μM) and p300/CPB-associated factor (PCAF, IC50 = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-135006A

Octahydroaminoacridine	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine can be used for Alzheimer's disease (AD) research .

HY-135006

Octahydroaminoacridine succinate	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine succinate, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine succinate can be used for Alzheimer's disease (AD) research .

HY-162339

BChE-IN-30	Cholinesterase (ChE)	Neurological Disease
BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC₅₀: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD .

HY-149993

hBChE-IN-2	Cholinesterase (ChE) Cannabinoid Receptor	Neurological Disease
hBChE-IN-2 (compound 15d) is a butyrylcholinesterase (BChE) inhibitor (IC₅₀ of 0.62 μM) and a cannabinoid receptor 2 (CB2R) agonist. hBChE-IN-2 has neuroprotection activities .

HY-146251

BuChE-IN-6	Cholinesterase (ChE) Amyloid-β	Neurological Disease
BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ₄₂ self-aggregation .

HY-121191

Bisnorcymserine N1,N8-Bisnorcymserine; (-)-Bisnorcymserine	Cholinesterase (ChE)	Neurological Disease
Bisnorcymserine ((-)-Bisnorcymserine) is an inhibitor for *butyrylcholinesterase* (BChE) with an IC₅₀ of 0.228 nM. Bisnorcymserine reduces the levels of amyloid-β peptide (Aβ), exhibits ameliorates the Alzheimer’s Disease in elderly rat models. Bisnorcymserine is blood-brain barrier penetrate .

HY-N10490

Blestrin D	Cholinesterase (ChE)	Neurological Disease
Blestrin D is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

HY-163883

BChE-IN-34	Cholinesterase (ChE)	Neurological Disease
BChE-IN-34 is a potent and selective butyrylcholinesterase (BChE) inhibitor with an IIC₅₀ of 25 nM. BChE-IN-34 shows excellent selectivity against BChE over acetylcholinesterase. BChE-IN-34 has neuroprotective and antioxidant effects .

HY-162340

Z32439948	Cholinesterase (ChE)	Neurological Disease
Z32439948 is a butyrylcholinesterase (BChE) inhibitor (IC₅₀: 1.4 μM, hBChE) and is a derivative of m-sulfamoylbenzamide. Z32439948 also exhibited neuroprotective effects against glutamate in SH-SY5Y cells .

HY-133776

Rivastigmine carbamate impurity 3-Nitrophenyl ethyl(methyl)carbamate	Cholinesterase (ChE)	Neurological Disease
Rivastigmine carbamate impurity (3-Nitrophenyl ethyl(methyl)carbamate) is an impurity of Rivastigmine. Rivastigmine is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively .

HY-157981

AChE-IN-60	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits monoamine oxidase (MAO)-A and MAO-B with IC₅₀s of 353 nM and 716 nM, respectively .

HY-170389

BChE-IN-39	Cholinesterase (ChE)	Neurological Disease
BChE-IN-39 (Compound 7c) is a selective inhibitor for *butyrylcholinesterase* (BChE) with an IC₅₀ of 0.08 μM (IC₅₀=3.98 μM for AChE). BChE-IN-39 downregulates the GSK-3β expression, inhibits the hyperphosphorylation of tau protein .

HY-124047

RX 67668	Cholinesterase (ChE)	Neurological Disease
RX 67668 is a potent *cholinesterase* inhibitor with an IC₅₀ of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. RX 67668 can reverse the neuromuscular blockade induced by D-tubocurarine. RX 67668 is a muscle relaxant used to relieve skeletal muscle fatigue .

HY-103373

PE154	Cholinesterase (ChE)	Neurological Disease
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and *butyrylcholinesterase* (BChE) (IC₅₀s=280 pM and 16 nM, respectively) . PE154 can label β-amyloid plaques in histochemical analysis .

HY-N10489

BChE-IN-12	Cholinesterase (ChE)	Neurological Disease
BChE-IN-12 (compound 12) is a potent butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀ value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

HY-N10486

BChE-IN-10	Cholinesterase (ChE)	Neurological Disease
BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

HY-155304

BuChE-IN-8	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-8 (compound 19c) is a butyrylcholinesterase (BuChE) inhibitor with an IC₅₀ of 559 nM. BuChE-IN-8 possesses human β-secretase (BACE1) and Aβ40 aggregation inhibitory activities. BuChE-IN-8 has significant antiamnesic properties .

HY-145833A

sEH/AChE-IN-4	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC₅₀ values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively .

HY-174328

BChE/AChE-IN-1	Cholinesterase (ChE)	Neurological Disease
BChE/AChE-IN-1 (Compound 4m) is a potent dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀ values of 0.7 μM and 0.2 μM, respectively. BChE/AChE-IN-1 is promising for research of neurodegenerative diseases such as Alzheimer’s disease (AD) .

HY-145833

sEH/AChE-IN-3	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-3 (compound (−)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC₅₀ values of 0.4 nM (hsEH), 1.94 nM (hAChE), 615 (hBChE, human butyrylcholinesterase), 4.3 nM (msEH), and 2.61 nM (mAChE), respectively .

HY-176432

BChE-IN-40	Cholinesterase (ChE)	Neurological Disease
BChE-IN-40 (compound D40) is a potent *butyrylcholinesterase* inhibitor with an IC₅₀ of 0.59 μM. BChE-IN-40 exhibits strong anti-inflammatory effects with an IC₅₀ of 4.55 μM for nitric oxide suppression. BChE-IN-40 demonstrates excellent blood-brain barrier permeability .

HY-144689

BChE-IN-3	Cholinesterase (ChE)	Neurological Disease
BChE-IN-3 (compound 45a) is a potent, selective, time-dependent and pseudoirreversible BChE inhibitor, with an IC₅₀ of 56.9 nM. BChE-IN-3 also shows marginal and reversible (not time-dependent) inhibition of AChE .

HY-151386

BChE-IN-13	Cholinesterase (ChE)	Neurological Disease
BChE-IN-13 (Compound 17c) is an orally active, potent and selective *Butyrylcholinesterase* (BChE) inhibitor with IC₅₀s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .

HY-163885

SSZ 1 Publications Verification	Cholinesterase (ChE) Beta-secretase γ-secretase	Neurological Disease
SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, *butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase*. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107569

Garcinol 5 Publications Verification	Classification of Application Fields Guttiferae Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Garcinia indica	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards *acetyl cholinesterase* (AChE)** and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 μM and 7.39 μM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-N6009

8-Deoxygartanin	Infection other families Xanthones Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	Parasite NF-κB
8-Deoxygartanin, a prenylated xanthones from G. mangostana, is a selective inhibitor of butyrylcholinesterase (BChE) . 8-Deoxygartanin exhibits antiplasmodial activity with an IC₅₀ of 11.8 μM for the W2 strain of Plasmodium falciparum . 8-Deoxygartanin inhibits NF-κB (p65) activation with an IC₅₀ of 11.3 μM .

HY-N10488

BChE-IN-11	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Polyphenols Plants Source Classification	Cholinesterase (ChE)
BChE-IN-11 (compound 10) is a potent, selective and non-competitive BChE (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

HY-N12581

Kuwanon U	Flavonoids Flavonones Morus alba L. Plants Moraceae Source Classification	Cholinesterase (ChE)
Kuwanon U is a potent *cholinesterase* inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-107569R

Garcinol (Standard)	Structural Classification Guttiferae Phenols Polyphenols Plants Garcinia indica	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite Reference Standards
Garcinol (Standard) is the analytical standard of Garcinol. This product is intended for research and analytical applications. Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50s of 0.66 μM and 7.39 μM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC50= 7 μM) and p300/CPB-associated factor (PCAF, IC50 = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-N10490

Blestrin D	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Polyphenols Plants Source Classification	Cholinesterase (ChE)
Blestrin D is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

HY-N10489

BChE-IN-12	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Polyphenols Plants Source Classification	Cholinesterase (ChE)
BChE-IN-12 (compound 12) is a potent butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀ value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

HY-N10486

BChE-IN-10	Bletilla striata (Thunb. ex Murray) Rchb. f. Classification of Application Fields Neurological Disease Orchidaceae Phenols Polyphenols Plants Disease Research Fields Source Classification	Cholinesterase (ChE)
BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

HY-N17425

Lakoochin C	Structural Classification Monophenols Phenols Artocarpus lakoocha Roxburgh Plants Moraceae Source Classification	Cholinesterase (ChE)
Lakoochin C is an inhibitor of acetylcholinesterase (AChE) (IC₅₀ = 61.86 μM) and butyrylcholinesterase (BChE) (IC₅₀ = 47.21 μM). Lakoochin C may be used in research related to Alzheimer's disease .

Cat. No.	Product Name	Chemical Structure

HY-17368S1

(Rac)-Rivastigmine-d6

(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S2

Rivastigmine-d3 hydrochloride

Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W654335

Rivastigmine-d4 tartrate

Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W654336

(S)-Rivastigmine-d4

(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks